Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLPG3667 in Systemic Lupus Erythematosus
NCT05856448Phase 2Completed
- Sponsor
- Galapagos NV
- Start
- Jun 2023
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 12
01
Overview
A Phase 2 trial of GLPG3667 in systemic lupus erythematosus (SLE), sponsored by Galapagos NV. Started Jun 2023; status: completed.
02
Drugs
GLPG3667
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT05856448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05856448.